JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Link
https://link.springer.com/content/pdf/10.1007/s10067-022-06471-x.pdf
Reference21 articles.
1. Fragoulis GE, McInnes IB, Siebert S (2019) JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 58:i43–i54. https://doi.org/10.1093/rheumatology/key276
2. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA, Investigators OS (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316–326. https://doi.org/10.1056/NEJMoa2109927
3. Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z (2022) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-222259
4. Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ (2022) Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 81:798–804. https://doi.org/10.1136/annrheumdis-2021-221915
5. Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E (2022) Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-222824
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study;Autoimmunity Reviews;2024-03
2. Cardiovascular disease in spondyloarthritis: a narrative review of risk factors and the effect of treatments;Current Opinion in Rheumatology;2023-12-20
3. Cardiovascular risk in axial spondyloarthritis—a systematic review;Clinical Rheumatology;2023-07-07
4. Profiling of patients with type 2 diabetes based on medication adherence data;Frontiers in Public Health;2023-07-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3